arrow
J

Jack F. Shern

National Cancer Institute
H指数:41
被引数:9,854

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FANCM is required for the PAX3::FOXO1-driven oncogenic program in rhabdomyosarcoma

FANCM在横纹肌肉瘤中对于PAX3::FOXO1驱动的癌基因程序是必需的

2026-09-010
OAAI
Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma

治疗性NAMPT抑制揭示了神经母细胞瘤中可靶向的代谢易损性

2026-08-050
OAAI
Integrated multiclass driver ctDNA profiling enables MPNST detection and monitoring in NF1 patients

整合多类驾驶员循环肿瘤DNA分析能够实现神经纤维瘤病1型患者的恶性周围神经鞘瘤的检测和监测

2026-07-040
OA
Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

新型药物在儿童非横纹肌肉瘤软组织肉瘤中的优先级排序及进一步研究的报告:来自儿童肿瘤组的报告

2025-07-060
PRE
The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children’s Oncology Group

遗传祖先对儿童横纹肌肉瘤生存结局的影响:美国儿童肿瘤学会报告

2025-06-090
OA
Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity

靶向SWI/SNF atp酶降低神经母细胞瘤细胞可塑性

2024-08-220
PRE
Targeting CDK8: A translatable therapeutic approach for fusion-positive aRMS
2024-03-220
PRE
KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma
2024-02-244
OAAI
Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome
2023-10-015
OA
Urine cell-free DNA multi-omics to detect molecular residual disease and predict survival in bladder cancer patients
2023-04-040
PRE
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
2023-01-1923
OAAI